Skip to main content
Premium Trial:

Request an Annual Quote

First-Issue Feedback. Phew. You Like It.

Premium

Today I read your inaugural issue of Genome Technology. Just great. Congratulation to the whole team! I cannot remember when I last read a journal from A to Z, but it''s a damned long time ago. Here I did, and I found it informative, motivating, with a good degree of novelty and content. It makes me eager to see and read the next issue. Unnecessary to say that LION will subscribe.

Friedrich von Bohlen, CEO, Lion Bioscience

 

Genome Technology is a dream come true! Genomics is a topic not well understood by many outside the field. Now there''s a publication for the rest of us, who, on a day-to-day basis must translate scientific information and notions into understandable analogies and compelling stories for professionals and executives whose last contact with fruit flies was in grade school experiments.

Your publication fills the void beyond trade and peer-reviewed press. Good luck!

Holly Hartz, Director, External Communications, Neomorphic

 

Just got a copy in the mail today … nice idea! How about adding a section on the financial side of the genomics world (alliances, deals, M&A, etc…)?

Wan Chi Lau, Sr. Manager Technology Transfer, Millennium Pharmaceuticals

 

Congratulations on a very nice publication! It’s been read by many here and the reviews are great. It''s very interesting and FUN ¯ as you promised.

Louise Bono, Marketing , Communications Manager, Spotfire

 

I was pleased to find a sample copy of Genome Technology in my mailbox today and read through the whole thing — it was time well spent.

Nat Goodman’s review of the bio-ifx portals was particularly cogent and informative. I am a bioinformatics scientist and enjoyed his nuanced perspective.

I commend you on a nice inaugural issue. I do have a comment about layout-the article/content copy and the ad copy are more similar than I’m used to, even in popular magazines. It was somewhat odd that the photos and text layout on the contents page(s) almost resembled ad layout.

Maybe this is conscious/ useful — I noticed it subconsciously at first then thought about it a bit later. At any rate, I did enjoy the 9/00 issue.

Hanif Khalak, Software Engineer, The Institute for Genomic Research

 

Send us a message! Drop us a line!

Email us your comments:

[email protected]

or snail mail them to: Editor, GenomeWeb

P.O. Box 998, Peck Slip Station
New York, NY 10272-0998

Please include your name, title, and company.

Letters may be edited for clarity and length.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.